Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were issued for nivolumab and ipilimumab dual checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moscetti, Luca, Hennik, Paula, Bolstad, Bjorg, Camarero, Jorge, Josephson, Filip, Melchiorri, Daniela, Sommerfelt Grønvold, Maja, Sjoberg, Jan, Botezatu, Mihaela, Mulder, Jorn, Meulendijks, Didier, Trullas Jimeno, Ana, Zafiropoulos, Nikolaos, Bergh, Jonas, Enzmann, Harald, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451283/
https://www.ncbi.nlm.nih.gov/pubmed/32847837
http://dx.doi.org/10.1136/esmoopen-2020-000856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451283/
https://www.ncbi.nlm.nih.gov/pubmed/32847837
http://dx.doi.org/10.1136/esmoopen-2020-000856

Ejemplares similares